The anti-Mullerian hormone (AMH) can be measured by a blood test and gives an indication of the number of oocytes in the ovaries, but not of oocyte quality . Whilst the test is helpful in assisted reproduction as it roughly indicates the potential number of oocytes retrievable for in vitro fertilization or oocyte freezing, the test cannot reliably predict the chance of conceiving or the age of menopause for individual women. As such, AMH testing for women outside of fertility treatment settings is strongly discouraged. Despite this, the test is increasingly promoted as a way for women to find out about their fertility or reproductive timeline. Online companies in the USA, Australia, The Netherlands, and elsewhere now sell the test direct-to-consumers, falsely promising women detailed insights into their fertility potential (Johnson et al., 2023). Inaccurate information about the AMH test has also been identified on other websites including accredited fertility clinic websites (Copp et al., 2021).
The post Women’s interest, knowledge, and attitudes relating to anti-Mullerian hormone testing: a randomized controlled trial – T Copp et al. appeared first on Wiser Healthcare.
